In vitro activity of fosfomycin in combination with various antistaphylococcal substances

被引:97
作者
Grif, K [1 ]
Dierich, MP [1 ]
Pfaller, K [1 ]
Miglioli, PA [1 ]
Allerberger, F [1 ]
机构
[1] Univ Innsbruck, Inst Hyg & Social Med, A-6020 Innsbruck, Austria
关键词
D O I
10.1093/jac/48.2.209
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Using the chequerboard technique we studied the in vitro activity of the broad spectrum antibiotic fosfomycin in combination with vancomycin, rifampicin, linezolid, quinupristin/dalfopristin, cefazolin, meropenem and moxifloxacin against two Staphylococcus epidermidis strains (ATCC 12228, DSM 3269) and five Staphylococcus aureus isolates (ATCC 29213, DSM 683, DSM 46320, GISA 323/93, MRSA 3558/00). The phenomena of 'trailing' and 'skipped wells' did not present a problem. Synergy was the most common effect of all drugs tested in combination with fosfomycin; only combination with vancomycin showed antagonism for two of seven isolates. Using a killing-curve technique fosfomycin showed cidal activity, where increasing the drug concentration above the MIC did not enhance killing velocity. Inhibitory concentrations of vancomycin plus fosfomycin against DSM 46320 caused effects identical to those observed with vancomycin alone. The combination of fosfomycin plus linezolid exerted the bacteriostatic effect found with linezolid alone. Fosfomycin plus quinupristin/dalfopristin exhibited the bactericidal effect found with fosfomycin alone (in contrast to the rapidly bactericidal effect of quinupristin/dalfopristin). Electron microscopy showed that fosfomycin given in combination with linezolid, quinupristin/dalfopristin or moxifloxacin (substances that do not cause morphological alterations when given alone) resulted in 'cauliflower-shaped' distortion as caused by fosfomycin alone. Our in vitro data indicate considerable potential for fosfomycin used in combination with other antistaphylococcal antimicrobials, especially linezolid or quinupristin/dalfopristin.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 26 条
[1]   In-vitro activity of fosfomycin against vancomycin-resistant enterococci [J].
Allerberger, F ;
Klare, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (02) :211-217
[2]   Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro [J].
Amorena, B ;
Gracia, E ;
Monzón, M ;
Leiva, J ;
Oteiza, C ;
Pérez, M ;
Alabart, JL ;
Hernández-Yago, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :43-55
[3]   INTERNATIONAL COLLABORATIVE STUDY ON STANDARDIZATION OF BACTERIAL SENSITIVITY TO FOSFOMYCIN [J].
ANDREWS, JM ;
BAQUERO, F ;
BELTRAN, JM ;
CANTON, E ;
CROKAERT, F ;
GOBERNADO, M ;
GOMEZLUS, R ;
LOZA, E ;
NAVARRO, M ;
OLAY, T ;
RODRIGUEZ, A ;
VICENTE, MV ;
WISE, R ;
YOURASSOWSKY, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 (04) :357-361
[4]   Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany [J].
Bierbaum, G ;
Fuchs, K ;
Lenz, W ;
Szekat, C ;
Sahl, HG .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (10) :691-696
[5]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[6]   Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates [J].
Boyle-Vavra, S ;
Berke, SK ;
Lee, JC ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :272-277
[7]   Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates [J].
Buxbaum, A ;
Straschil, U ;
Moser, C ;
Graninger, W ;
Georgopoulos, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :13-18
[8]  
CHIN NX, 1987, FOSFOMYCIN
[9]   Activity of trovafloxacin, alone and in combination with other agents, against Enterobacteriaceae by time-kill analysis [J].
Clark, CL ;
Kelly, LM ;
Jacobs, MR ;
Appelbaum, PC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (07) :565-567
[10]   INVITRO ACTIVITY OF IMIPENEM AGAINST ENTEROCOCCI AND STAPHYLOCOCCI AND EVIDENCE FOR HIGH-RATES OF SYNERGISM WITH TEICOPLANIN, FOSFOMYCIN, AND RIFAMPIN [J].
DEBBIA, E ;
VARALDO, PE ;
SCHITO, GC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (05) :813-815